![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Publisher: Bentham Science Publishers
E-ISSN: 1873-4286|8|20|1837-1844
ISSN: 1381-6128
Source: Current Pharmaceutical Design, Vol.8, Iss.20, 2002-09, pp. : 1837-1844
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
By Higgins G.A. Kilpatrick G.J.
Expert Opinion on Investigational Drugs, Vol. 8, Iss. 12, 1999-12 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Clinical development of endothelin receptor antagonists
By Douglas S.A.
Trends in Pharmacological Sciences, Vol. 18, Iss. 11, 1997-11 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
DP2 receptor antagonists in development
By Norman Peter
Expert Opinion on Investigational Drugs, Vol. 19, Iss. 8, 2010-08 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
5-HT 1B/D Receptor Antagonists
By Pauwels P.J.
General Pharmacology, Vol. 29, Iss. 3, 1997-09 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Advances in use of the 5-HT3 receptor antagonists
By Walton S.M.
Expert Opinion on Pharmacotherapy, Vol. 1, Iss. 2, 2000-01 ,pp. :